Stonebridge Capital Management Inc. Buys New Position in Stryker Corporation $SYK

Stonebridge Capital Management Inc. purchased a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, HoldingsChannel reports. The firm purchased 16,050 shares of the medical technology company’s stock, valued at approximately $5,053,000. Stryker makes up 2.4% of Stonebridge Capital Management Inc.’s investment portfolio, making the stock its 13th largest holding.

Several other hedge funds and other institutional investors have also modified their holdings of SYK. Brighton Jones LLC boosted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in shares of Stryker during the second quarter valued at about $205,000. Marshall Wace LLP lifted its stake in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC bought a new position in Stryker during the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the 2nd quarter valued at approximately $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Price Performance

Stryker stock opened at $330.08 on Thursday. The business’s 50-day simple moving average is $328.37 and its 200 day simple moving average is $331.72. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $126.61 billion, a price-to-earnings ratio of 34.21, a P/E/G ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research reports. Citizens Jmp lowered their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Needham & Company LLC decreased their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Citigroup reissued a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Finally, Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.